Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADD UP trial of albendazole added to anti-TNF monotherapy in Crohn's disease
NL-OMON20630Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Crohn's disease comparing Albendazole + continued anti-TNF with Placebo + continued anti-TNF (2 arms). Primary endpoint: Absence of ulcers on centrally read endoscopy at week 12. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
albendazole
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON20630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20630.